Brad Loncar discusses the rallies in both Moderna and Regeneron following their quarterly results. Moderna's earnings and revenue blew past expectation, despite the company warning of declining profit as a result of unused Covid-19 vaccines. Regeneron also beat on top and bottom line, amid record sales of several of its products. Tom White then breaks down a bullish example trade in Moderna and a neutral to bullish trade in Regeneron.
Morning Trade Live
04 Aug 2022
SHARE
Trading 360
03 Aug 2023
Morning Trade Live
10 May 2023
Trading 360
01 Aug 2023
Market On Close
27 Jun 2023
Morning Trade Live
10 Jul 2023
Morning Trade Live
08 Jun 2023